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Effect of Carboplatin in Patients with TNBC
3 yr DFS 85.8%
3 yr DFS 76.1%
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Conclusion
 Carboplatin induces a significantly (HR=0.56, p=0.035) improved diseasefree survival in patients with TNBC but not in patients with HER2-positive disease (HR 1.33, p=0.372) (Interaction Test p=0.046).
 Survival effect of carboplatin was correctly predicted by its effect on pCR, supporting surrogacy of pCR in case of large pCR differences (like NOAH trial). Bevacizumab 10 mg/kg q2wks x 9
Bevacizumab 10 mg/kg q2wks x 9
Carboplatin AUC 6 q3wks x 4
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BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto Study .
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HER2-negative part

Conclusion
 Patients with BRCA1 or BRCA2 mutations have significantly higher pCR rates after a neoadjuvant chemotherapy.
 The effect seems to be stronger in patients treated with bevacizumab.
 BRCA1/2 mutations had a marginal effect on prognosis.
 The effect of pCR on prognosis was smaller in patients with a BRCA1/2 mutation, than in patients with wildtype genotype, but test for interaction was not significant. This presentation is the intellectual property of the author/presenter. Contact wolfgang.janni@uniklinik-ulm.de for permission to reprint and/or distribute.
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SUCCESS A -study design
Patient characteristics
 3754 patients with high-risk early breast cancer (defined as pN1-3, or pT2-4, or G3, or hormone receptor negative, or age ≤ 35) randomized for SUCCESS A  Data from 1087 patients with CTC determination both before and two years after chemotherapy available for analysis  No significant differences with regard to patient and tumor characteristics between the 1087 patients included and the remaining 2667 patients (all p > 0.05) This presentation is the intellectual property of the author/presenter. Contact wolfgang.janni@uniklinik-ulm.de for permission to reprint and/or distribute.
198 (18.2%) of the 1087 patients with at least one CTC in the blood two years after adjuvant chemotherapy (median 1 CTC, range 1 -99 CTCs)
Results I: Prevalence of CTCs after two years
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Results IV: Prognostic value of CTCs assessed two years after adjuvant chemotherapy
Results V: Subgroups -CTC status before and two years after adjuvant chemotherapy
VM14 FT4
Summary
 198 (18.2%) of 1087 patients with at least one CTC in the blood two years after adjuvant chemotherapy  Presence of CTCs two years after adjuvant chemotherapy is a significant independent prognostic factor for poor OS and DFS  Patients with CTCs both before and two years after adjuvant chemotherapy had worst survival outcome  The prognostic value of the presence of CTCs two years after chemotherapy was not evident for patients with HER2-positive tumors (but no significant interaction between presence of CTCs two years after adjuvant chemotherapy and biological subtype) According to the safety interim analysis of the first 50 pts treated with 6 cycles of X, the IDMC recommended extending X to 8 cycles. 
Compliance of capecitabine
Subgroup
Analysis for DFS
Control better
Conclusions
 After standard neoadjuvant chemotherapy containing A and/or T, postoperative adjuvant use of capecitabine improved DFS significantly in HER2-negative primary breast cancer patients with pathologically proven residual invasive disease.  OS was significantly improved by capecitabine adjuvant therapy for non-pCR or node-positive patients after NAC.  The balance of benefit and toxicity would favor the use of capecitabine in the post-NAC situation, but prediction for the therapeutic benefit needs to be investigated further.  The cost-effectiveness analysis will be carried out. 
Avelumab* (MSB0010718C)
This presentation is the intellectual property of Luc Y. Dirix. Contact luc.dirix@gza.be for permission to reprint and/or distribute. • Fully human anti-PD-L1 IgG1 antibody 1
• Binds PD-L1 1 -Inhibits PD-1/PD-L1 interactions -Leaves PD-1/PD-L2 pathway intact
• Half-life ≈4-5 days; >95% TO over whole 2-week dosing period at 10 mg/kg dose 2
• ADCC may contribute to activity, as shown in preclinical models 3
• Doses up to 20 mg/kg Q2W safely administered 1,2
• Antitumor activity in patients with lung, gastric, ovarian, bladder, and other malignancies, all unselected for PD-L1 expression [4] [5] [6] [7] San Antonio Breast Cancer Symposium -December 8-12, 2015 Phase Ib cohort expansion This presentation is the intellectual property of Luc Y. Dirix. Contact luc.dirix@gza.be for permission to reprint and/or distribute.
San Antonio Breast Cancer Symposium -December 8-12, 2015 • Median duration of F/U: 10.0 months (range, 6.0-15.2 months)
• Median time to response: 11.4 weeks (range, 5.7-17.7 weeks)
• Median DoR: 28.7 weeks (95% CI: 6.1, ne)
• Responses observed in patients with different molecular subtypes
• Response ongoing in 5/8 patients at time of analysis
This presentation is the intellectual property of Luc Y. Dirix. Contact luc.dirix@gza.be for permission to reprint and/or distribute.
Time to and duration of response
San Antonio Breast Cancer Symposium -December 8-12, 2015 • Tumor shrinkage by ≥30% was observed in 16 patients (9.5%) in overall MBC population, including 2 patients with PD by RECIST who had PRs by modified irRC
• 17.2% (10/58) of TNBC patients had tumor shrinkage of ≥30%
* Number of patients with baseline tumor assessments and ≥1 post-baseline assessment. 
Best change in target lesions
Conclusions
• Avelumab has an acceptable safety profile in patients with MBC
• Despite low ORR in overall unselected MBC cohort, signs of greater clinical activity in specific subsets of patients • Further analysis of PD-L1 expression and clinical activity of avelumab in MBC is ongoing
